

Rheumatology & ILD Summit

27 February - 01 March 2026
Porto, Portugal

rheumatology-ildsummit.org

Scientific Program: Autoimmune Diseases and Pulmonary Fibrosis: Recent Advances

This program is designed for a multi-day symposium, bringing together rheumatologists, pulmonologists, and translational researchers to explore the intersection of systemic autoimmunity and interstitial lung disease (ILD).

27 February 2026, Friday

09:45-10:00 Welcome- *Nevsun İnanç, Antonio Marinho*

10:00-12:00 Pathophysiology and the Shared Genetic Landscape

Focus: Understanding why the immune system targets the lung parenchyma.

Chair: *Antonio Marinho, Gülen Hatemi*

10:00-10:30 The "Two-Hit" Hypothesis: How environmental triggers and genetic susceptibility lead to Autoimmune ILD- *Alper Sari*

10:30-11:00 Beyond the Joint: New insights into the lung as the primary site of autoimmune initiation in Rheumatoid Arthritis (RA)- *Nevsun İnanç*

11:00-11:30 Biomarkers for predicting the occurrence and progression of ILD - *Berkan Armağan*

11:30-12:00 Mechanisms of fibrosis: different pathways in different organs- *Murat İnanç*

12:00-13:30 Lunch Break

13:30-14:30 The Microbiome Link: How the lung-gut axis influences systemic immune activation and pulmonary scarring

Chair: *Sedat Kiraz, Pedro Leuchner*

- Lung axis- *Agostinho Rodrigues Carvalho*
- Gut axis- *Daniel Oliveira*

Rheumatology & ILD Summit

27 February - 01 March 2026
Porto, Portugal

rheumatology-ildsummit.org

14:30-15:00 Coffee Break

15:00-16:30 Panel Discussion: Redefining "IPAF" (Interstitial Pneumonia with Autoimmune Features) – Are we closer to a formal diagnosis?

Chair: *Süleyman Serdar Koca, Raquel Faria*

15:00-15:30 Rheumatologic Approach- *Ediz Dalkılıç*

15:30-16:00 Pulmonology Approach- *Özlem Özdemir Kumbasar*

16:00-16:30 Discussion

28 February 2026, Saturday

Emerging Biomarkers and Diagnostic Precision

Focus: Improving early detection and predicting disease progression.

09:00-10:30 Serological Breakthroughs

Chair: *Serdal Uğurlu, Carlos Vasconcelos*

09:00-09:30 Utilizing novel myositis-specific antibodies (MSAs) to predict rapidly progressive ILD- *Gökçe Kenar Artım*

09:30-10:00 MCTD & Anti-U1RNP: Why 40% of U1RNP-positive patients develop ILD and the significance of the NSIP (Non-Specific Interstitial Pneumonia) pattern- *Mehmet Engin Tezcan*

10:00-10:30 The Sjögren's-ILD Phenotype: Beyond "Sicca"—Identifying Anti-Ro52 as a high-risk marker for progressive fibrosis- *Ivone Valadão*

Rheumatology & ILD Summit

27 February - 01 March 2026
Porto, Portugal

rheumatology-ildsummit.org

10:30-11:00 Coffee Break

Chair: *Nuno Cortesão, Nevsun İnanç*

11:00-11:30 Using the lung Ultrasound to quantify pulmonary severity- ***Gökhan Sargin***

11:30-12:00 **AI in Radiology:** Leveraging machine learning for the early quantification of subclinical fibrosis- ***Mustafa Erdogan***

12:00-13:30 Lunch Break

13:30-14:30 Pulmonary Arterial Hypertension (PAH)

Chair: *Mário Santos, Murat İnanç*

13:30-14:00 Beyond parenchymal disease—Managing the lethal combination of ILD and CTD in PH- ***Ali Akdoğan***

14:00-14:30 Can we differentiate PAH from PH related with ILD- ***Nesrin Moğulkoç***

14:30-15:00 Coffee Break

Chair: *Yavuz Pehlivan, Inês Furtado*

15:00-16:00 **Workshop 1:** Interpreting HRCT Patterns: Identifying UIP vs. NSIP in the autoimmune patient- ***Derya Kocakaya, Göksel AltuŞık Ergür***

16:00-17:30 **Workshop 2:** Basic lung echography workshop- ***Nuno Cortesão***

Rheumatology & ILD Summit

27 February - 01 March 2026
Porto, Portugal

rheumatology-ildsummit.org

01 March 2026, Sunday

The New Therapeutic Era

Focus: Moving from traditional immunosuppression to "Niche" and "Combination" therapies.

09:30-10:30 Targeted Biologics

Chair: Cemal Bes, Isabel Almeida

09:30-10:00 Treatment strategies for RA-related interstitial lung disease- **Ender Terzioğlu**

10:00-10:30 The emergence of JAK inhibitors for refractory Dermatomyositis-ILD- **Ana Campar**

10:30-11:00 Coffee Break

Chair: Nesrin Moğulkoç, Antonio Marinho

11:00-11:30 **Is there room for MTX in ILD treatment:** Recent data (including the PULMORA trial)- **Ivo Barreiro**

11:30-12:30 Future Frontiers

11:30-12:00 Antifibrotic Strategies in ILD: Current Evidence and Future Perspectives- **Sehnaz Yıldızeli**

12:00-12:30 Precision Medicine—Tailoring therapy based on molecular endotypes rather than clinical labels- **José Delgado Alves**

Closing remarks: **Nevsun İnanç, Antonio Marinho**